nodes	percent_of_prediction	percent_of_DWPC	metapath
Thiabendazole—Hyperglycaemia—Ifosfamide—testicular cancer	0.00641	0.00641	CcSEcCtD
Thiabendazole—Stevens-Johnson syndrome—Ifosfamide—testicular cancer	0.00628	0.00628	CcSEcCtD
Thiabendazole—Flushing—Bleomycin—testicular cancer	0.00618	0.00618	CcSEcCtD
Thiabendazole—Confusional state—Chlorambucil—testicular cancer	0.00616	0.00616	CcSEcCtD
Thiabendazole—Leukopenia—Vinblastine—testicular cancer	0.00614	0.00614	CcSEcCtD
Thiabendazole—Haematuria—Ifosfamide—testicular cancer	0.00604	0.00604	CcSEcCtD
Thiabendazole—Chills—Bleomycin—testicular cancer	0.00597	0.00597	CcSEcCtD
Thiabendazole—Liver injury—Epirubicin—testicular cancer	0.00596	0.00596	CcSEcCtD
Thiabendazole—Convulsion—Vinblastine—testicular cancer	0.00594	0.00594	CcSEcCtD
Thiabendazole—Erythema multiforme—Dactinomycin—testicular cancer	0.00587	0.00587	CcSEcCtD
Thiabendazole—Anorexia—Chlorambucil—testicular cancer	0.00582	0.00582	CcSEcCtD
Thiabendazole—Flushing—Dactinomycin—testicular cancer	0.00576	0.00576	CcSEcCtD
Thiabendazole—Chills—Dactinomycin—testicular cancer	0.00557	0.00557	CcSEcCtD
Thiabendazole—Liver injury—Doxorubicin—testicular cancer	0.00551	0.00551	CcSEcCtD
Thiabendazole—Visual impairment—Ifosfamide—testicular cancer	0.00548	0.00548	CcSEcCtD
Thiabendazole—Erythema multiforme—Ifosfamide—testicular cancer	0.00538	0.00538	CcSEcCtD
Thiabendazole—Dyspepsia—Chlorambucil—testicular cancer	0.00538	0.00538	CcSEcCtD
Thiabendazole—Anorexia—Vinblastine—testicular cancer	0.00534	0.00534	CcSEcCtD
Thiabendazole—Decreased appetite—Chlorambucil—testicular cancer	0.00531	0.00531	CcSEcCtD
Thiabendazole—Tinnitus—Ifosfamide—testicular cancer	0.0053	0.0053	CcSEcCtD
Thiabendazole—Flushing—Ifosfamide—testicular cancer	0.00528	0.00528	CcSEcCtD
Thiabendazole—Fatigue—Chlorambucil—testicular cancer	0.00527	0.00527	CcSEcCtD
Thiabendazole—Leukopenia—Bleomycin—testicular cancer	0.00519	0.00519	CcSEcCtD
Thiabendazole—Coordination abnormal—Epirubicin—testicular cancer	0.00511	0.00511	CcSEcCtD
Thiabendazole—Chills—Ifosfamide—testicular cancer	0.0051	0.0051	CcSEcCtD
Thiabendazole—Feeling abnormal—Chlorambucil—testicular cancer	0.00503	0.00503	CcSEcCtD
Thiabendazole—Hepatocellular injury—Epirubicin—testicular cancer	0.00502	0.00502	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Chlorambucil—testicular cancer	0.005	0.005	CcSEcCtD
Thiabendazole—Stevens-Johnson syndrome—Etoposide—testicular cancer	0.00496	0.00496	CcSEcCtD
Thiabendazole—Jaundice—Etoposide—testicular cancer	0.00488	0.00488	CcSEcCtD
Thiabendazole—Decreased appetite—Vinblastine—testicular cancer	0.00487	0.00487	CcSEcCtD
Thiabendazole—Leukopenia—Dactinomycin—testicular cancer	0.00484	0.00484	CcSEcCtD
Thiabendazole—Abdominal pain—Chlorambucil—testicular cancer	0.00483	0.00483	CcSEcCtD
Thiabendazole—Confusional state—Bleomycin—testicular cancer	0.00477	0.00477	CcSEcCtD
Thiabendazole—Anaphylactic shock—Bleomycin—testicular cancer	0.00473	0.00473	CcSEcCtD
Thiabendazole—Visual impairment—Cisplatin—testicular cancer	0.00473	0.00473	CcSEcCtD
Thiabendazole—Coordination abnormal—Doxorubicin—testicular cancer	0.00473	0.00473	CcSEcCtD
Thiabendazole—Vision blurred—Ifosfamide—testicular cancer	0.00467	0.00467	CcSEcCtD
Thiabendazole—Hepatocellular injury—Doxorubicin—testicular cancer	0.00464	0.00464	CcSEcCtD
Thiabendazole—Feeling abnormal—Vinblastine—testicular cancer	0.00461	0.00461	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Vinblastine—testicular cancer	0.00458	0.00458	CcSEcCtD
Thiabendazole—Tinnitus—Cisplatin—testicular cancer	0.00457	0.00457	CcSEcCtD
Thiabendazole—Lymphadenopathy—Methotrexate—testicular cancer	0.00456	0.00456	CcSEcCtD
Thiabendazole—Flushing—Cisplatin—testicular cancer	0.00455	0.00455	CcSEcCtD
Thiabendazole—Angioedema—Ifosfamide—testicular cancer	0.00452	0.00452	CcSEcCtD
Thiabendazole—Anorexia—Bleomycin—testicular cancer	0.00451	0.00451	CcSEcCtD
Thiabendazole—Hypersensitivity—Chlorambucil—testicular cancer	0.0045	0.0045	CcSEcCtD
Thiabendazole—Hypoaesthesia—Etoposide—testicular cancer	0.00447	0.00447	CcSEcCtD
Thiabendazole—Leukopenia—Ifosfamide—testicular cancer	0.00443	0.00443	CcSEcCtD
Thiabendazole—Abdominal pain—Vinblastine—testicular cancer	0.00443	0.00443	CcSEcCtD
Thiabendazole—Hypotension—Bleomycin—testicular cancer	0.00442	0.00442	CcSEcCtD
Thiabendazole—Asthenia—Chlorambucil—testicular cancer	0.00438	0.00438	CcSEcCtD
Thiabendazole—Hepatic failure—Methotrexate—testicular cancer	0.00433	0.00433	CcSEcCtD
Thiabendazole—Pruritus—Chlorambucil—testicular cancer	0.00432	0.00432	CcSEcCtD
Thiabendazole—Convulsion—Ifosfamide—testicular cancer	0.00429	0.00429	CcSEcCtD
Thiabendazole—Lymphadenopathy—Epirubicin—testicular cancer	0.00427	0.00427	CcSEcCtD
Thiabendazole—Erythema multiforme—Etoposide—testicular cancer	0.00425	0.00425	CcSEcCtD
Thiabendazole—Anorexia—Dactinomycin—testicular cancer	0.0042	0.0042	CcSEcCtD
Thiabendazole—Diarrhoea—Chlorambucil—testicular cancer	0.00418	0.00418	CcSEcCtD
Thiabendazole—Flushing—Etoposide—testicular cancer	0.00417	0.00417	CcSEcCtD
Thiabendazole—Hypersensitivity—Vinblastine—testicular cancer	0.00413	0.00413	CcSEcCtD
Thiabendazole—Decreased appetite—Bleomycin—testicular cancer	0.00411	0.00411	CcSEcCtD
Thiabendazole—Confusional state—Ifosfamide—testicular cancer	0.00408	0.00408	CcSEcCtD
Thiabendazole—Hepatic failure—Epirubicin—testicular cancer	0.00405	0.00405	CcSEcCtD
Thiabendazole—Anaphylactic shock—Ifosfamide—testicular cancer	0.00404	0.00404	CcSEcCtD
Thiabendazole—Chills—Etoposide—testicular cancer	0.00403	0.00403	CcSEcCtD
Thiabendazole—Vision blurred—Cisplatin—testicular cancer	0.00402	0.00402	CcSEcCtD
Thiabendazole—Asthenia—Vinblastine—testicular cancer	0.00402	0.00402	CcSEcCtD
Thiabendazole—Lymphadenopathy—Doxorubicin—testicular cancer	0.00395	0.00395	CcSEcCtD
Thiabendazole—Feeling abnormal—Bleomycin—testicular cancer	0.0039	0.0039	CcSEcCtD
Thiabendazole—Vomiting—Chlorambucil—testicular cancer	0.00388	0.00388	CcSEcCtD
Thiabendazole—Anorexia—Ifosfamide—testicular cancer	0.00385	0.00385	CcSEcCtD
Thiabendazole—Decreased appetite—Dactinomycin—testicular cancer	0.00383	0.00383	CcSEcCtD
Thiabendazole—Diarrhoea—Vinblastine—testicular cancer	0.00383	0.00383	CcSEcCtD
Thiabendazole—Leukopenia—Cisplatin—testicular cancer	0.00382	0.00382	CcSEcCtD
Thiabendazole—Fatigue—Dactinomycin—testicular cancer	0.0038	0.0038	CcSEcCtD
Thiabendazole—Hypotension—Ifosfamide—testicular cancer	0.00378	0.00378	CcSEcCtD
Thiabendazole—Hepatic failure—Doxorubicin—testicular cancer	0.00375	0.00375	CcSEcCtD
Thiabendazole—Dizziness—Vinblastine—testicular cancer	0.0037	0.0037	CcSEcCtD
Thiabendazole—Convulsion—Cisplatin—testicular cancer	0.0037	0.0037	CcSEcCtD
Thiabendazole—Feeling abnormal—Dactinomycin—testicular cancer	0.00363	0.00363	CcSEcCtD
Thiabendazole—Nausea—Chlorambucil—testicular cancer	0.00363	0.00363	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Dactinomycin—testicular cancer	0.00361	0.00361	CcSEcCtD
Thiabendazole—Somnolence—Ifosfamide—testicular cancer	0.00359	0.00359	CcSEcCtD
Thiabendazole—Vomiting—Vinblastine—testicular cancer	0.00356	0.00356	CcSEcCtD
Thiabendazole—Decreased appetite—Ifosfamide—testicular cancer	0.00351	0.00351	CcSEcCtD
Thiabendazole—Headache—Vinblastine—testicular cancer	0.00351	0.00351	CcSEcCtD
Thiabendazole—Leukopenia—Etoposide—testicular cancer	0.0035	0.0035	CcSEcCtD
Thiabendazole—Abdominal pain—Dactinomycin—testicular cancer	0.00349	0.00349	CcSEcCtD
Thiabendazole—Fatigue—Ifosfamide—testicular cancer	0.00348	0.00348	CcSEcCtD
Thiabendazole—Anaphylactic shock—Cisplatin—testicular cancer	0.00348	0.00348	CcSEcCtD
Thiabendazole—Hypersensitivity—Bleomycin—testicular cancer	0.00348	0.00348	CcSEcCtD
Thiabendazole—Asthenia—Bleomycin—testicular cancer	0.00339	0.00339	CcSEcCtD
Thiabendazole—Convulsion—Etoposide—testicular cancer	0.00339	0.00339	CcSEcCtD
Thiabendazole—Pruritus—Bleomycin—testicular cancer	0.00335	0.00335	CcSEcCtD
Thiabendazole—Feeling abnormal—Ifosfamide—testicular cancer	0.00333	0.00333	CcSEcCtD
Thiabendazole—Nausea—Vinblastine—testicular cancer	0.00333	0.00333	CcSEcCtD
Thiabendazole—Anorexia—Cisplatin—testicular cancer	0.00332	0.00332	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Ifosfamide—testicular cancer	0.0033	0.0033	CcSEcCtD
Thiabendazole—Hypotension—Cisplatin—testicular cancer	0.00326	0.00326	CcSEcCtD
Thiabendazole—Hypersensitivity—Dactinomycin—testicular cancer	0.00325	0.00325	CcSEcCtD
Thiabendazole—Confusional state—Etoposide—testicular cancer	0.00322	0.00322	CcSEcCtD
Thiabendazole—Abdominal pain—Ifosfamide—testicular cancer	0.00319	0.00319	CcSEcCtD
Thiabendazole—Anaphylactic shock—Etoposide—testicular cancer	0.00319	0.00319	CcSEcCtD
Thiabendazole—Asthenia—Dactinomycin—testicular cancer	0.00316	0.00316	CcSEcCtD
Thiabendazole—Anorexia—Etoposide—testicular cancer	0.00304	0.00304	CcSEcCtD
Thiabendazole—Decreased appetite—Cisplatin—testicular cancer	0.00303	0.00303	CcSEcCtD
Thiabendazole—Diarrhoea—Dactinomycin—testicular cancer	0.00302	0.00302	CcSEcCtD
Thiabendazole—Vomiting—Bleomycin—testicular cancer	0.00301	0.00301	CcSEcCtD
Thiabendazole—Drowsiness—Methotrexate—testicular cancer	0.003	0.003	CcSEcCtD
Thiabendazole—Hypotension—Etoposide—testicular cancer	0.00298	0.00298	CcSEcCtD
Thiabendazole—Rash—Bleomycin—testicular cancer	0.00298	0.00298	CcSEcCtD
Thiabendazole—Dermatitis—Bleomycin—testicular cancer	0.00298	0.00298	CcSEcCtD
Thiabendazole—Hypersensitivity—Ifosfamide—testicular cancer	0.00298	0.00298	CcSEcCtD
Thiabendazole—Stevens-Johnson syndrome—Methotrexate—testicular cancer	0.00297	0.00297	CcSEcCtD
Thiabendazole—Asthenia—Ifosfamide—testicular cancer	0.0029	0.0029	CcSEcCtD
Thiabendazole—Feeling abnormal—Cisplatin—testicular cancer	0.00287	0.00287	CcSEcCtD
Thiabendazole—Pruritus—Ifosfamide—testicular cancer	0.00286	0.00286	CcSEcCtD
Thiabendazole—Haematuria—Methotrexate—testicular cancer	0.00286	0.00286	CcSEcCtD
Thiabendazole—Hyperglycaemia—Epirubicin—testicular cancer	0.00284	0.00284	CcSEcCtD
Thiabendazole—Somnolence—Etoposide—testicular cancer	0.00284	0.00284	CcSEcCtD
Thiabendazole—Nausea—Bleomycin—testicular cancer	0.00281	0.00281	CcSEcCtD
Thiabendazole—Drowsiness—Epirubicin—testicular cancer	0.00281	0.00281	CcSEcCtD
Thiabendazole—Vomiting—Dactinomycin—testicular cancer	0.0028	0.0028	CcSEcCtD
Thiabendazole—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.00278	0.00278	CcSEcCtD
Thiabendazole—Rash—Dactinomycin—testicular cancer	0.00278	0.00278	CcSEcCtD
Thiabendazole—Decreased appetite—Etoposide—testicular cancer	0.00277	0.00277	CcSEcCtD
Thiabendazole—Diarrhoea—Ifosfamide—testicular cancer	0.00277	0.00277	CcSEcCtD
Thiabendazole—Fatigue—Etoposide—testicular cancer	0.00275	0.00275	CcSEcCtD
Thiabendazole—Jaundice—Epirubicin—testicular cancer	0.00273	0.00273	CcSEcCtD
Thiabendazole—Haematuria—Epirubicin—testicular cancer	0.00267	0.00267	CcSEcCtD
Thiabendazole—Dizziness—Ifosfamide—testicular cancer	0.00267	0.00267	CcSEcCtD
Thiabendazole—Feeling abnormal—Etoposide—testicular cancer	0.00263	0.00263	CcSEcCtD
Thiabendazole—Hyperglycaemia—Doxorubicin—testicular cancer	0.00263	0.00263	CcSEcCtD
Thiabendazole—Nausea—Dactinomycin—testicular cancer	0.00262	0.00262	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Etoposide—testicular cancer	0.00261	0.00261	CcSEcCtD
Thiabendazole—Drowsiness—Doxorubicin—testicular cancer	0.0026	0.0026	CcSEcCtD
Thiabendazole—Visual impairment—Methotrexate—testicular cancer	0.00259	0.00259	CcSEcCtD
Thiabendazole—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.00257	0.00257	CcSEcCtD
Thiabendazole—Vomiting—Ifosfamide—testicular cancer	0.00257	0.00257	CcSEcCtD
Thiabendazole—Hypersensitivity—Cisplatin—testicular cancer	0.00257	0.00257	CcSEcCtD
Thiabendazole—Rash—Ifosfamide—testicular cancer	0.00255	0.00255	CcSEcCtD
Thiabendazole—Dermatitis—Ifosfamide—testicular cancer	0.00255	0.00255	CcSEcCtD
Thiabendazole—Erythema multiforme—Methotrexate—testicular cancer	0.00254	0.00254	CcSEcCtD
Thiabendazole—Jaundice—Doxorubicin—testicular cancer	0.00253	0.00253	CcSEcCtD
Thiabendazole—Abdominal pain—Etoposide—testicular cancer	0.00252	0.00252	CcSEcCtD
Thiabendazole—Tinnitus—Methotrexate—testicular cancer	0.00251	0.00251	CcSEcCtD
Thiabendazole—Hypoaesthesia—Epirubicin—testicular cancer	0.00251	0.00251	CcSEcCtD
Thiabendazole—Asthenia—Cisplatin—testicular cancer	0.0025	0.0025	CcSEcCtD
Thiabendazole—Haematuria—Doxorubicin—testicular cancer	0.00248	0.00248	CcSEcCtD
Thiabendazole—Visual impairment—Epirubicin—testicular cancer	0.00243	0.00243	CcSEcCtD
Thiabendazole—Chills—Methotrexate—testicular cancer	0.00241	0.00241	CcSEcCtD
Thiabendazole—Nausea—Ifosfamide—testicular cancer	0.0024	0.0024	CcSEcCtD
Thiabendazole—Diarrhoea—Cisplatin—testicular cancer	0.00238	0.00238	CcSEcCtD
Thiabendazole—Erythema multiforme—Epirubicin—testicular cancer	0.00238	0.00238	CcSEcCtD
Thiabendazole—Hypersensitivity—Etoposide—testicular cancer	0.00235	0.00235	CcSEcCtD
Thiabendazole—Tinnitus—Epirubicin—testicular cancer	0.00235	0.00235	CcSEcCtD
Thiabendazole—Flushing—Epirubicin—testicular cancer	0.00234	0.00234	CcSEcCtD
Thiabendazole—Hypoaesthesia—Doxorubicin—testicular cancer	0.00232	0.00232	CcSEcCtD
Thiabendazole—Asthenia—Etoposide—testicular cancer	0.00229	0.00229	CcSEcCtD
Thiabendazole—Chills—Epirubicin—testicular cancer	0.00226	0.00226	CcSEcCtD
Thiabendazole—Pruritus—Etoposide—testicular cancer	0.00226	0.00226	CcSEcCtD
Thiabendazole—Visual impairment—Doxorubicin—testicular cancer	0.00225	0.00225	CcSEcCtD
Thiabendazole—Vomiting—Cisplatin—testicular cancer	0.00222	0.00222	CcSEcCtD
Thiabendazole—Vision blurred—Methotrexate—testicular cancer	0.00221	0.00221	CcSEcCtD
Thiabendazole—Erythema multiforme—Doxorubicin—testicular cancer	0.0022	0.0022	CcSEcCtD
Thiabendazole—Rash—Cisplatin—testicular cancer	0.0022	0.0022	CcSEcCtD
Thiabendazole—Dermatitis—Cisplatin—testicular cancer	0.00219	0.00219	CcSEcCtD
Thiabendazole—Diarrhoea—Etoposide—testicular cancer	0.00218	0.00218	CcSEcCtD
Thiabendazole—Tinnitus—Doxorubicin—testicular cancer	0.00217	0.00217	CcSEcCtD
Thiabendazole—Flushing—Doxorubicin—testicular cancer	0.00216	0.00216	CcSEcCtD
Thiabendazole—Dizziness—Etoposide—testicular cancer	0.00211	0.00211	CcSEcCtD
Thiabendazole—Leukopenia—Methotrexate—testicular cancer	0.0021	0.0021	CcSEcCtD
Thiabendazole—Chills—Doxorubicin—testicular cancer	0.00209	0.00209	CcSEcCtD
Thiabendazole—Nausea—Cisplatin—testicular cancer	0.00207	0.00207	CcSEcCtD
Thiabendazole—Vision blurred—Epirubicin—testicular cancer	0.00207	0.00207	CcSEcCtD
Thiabendazole—Convulsion—Methotrexate—testicular cancer	0.00203	0.00203	CcSEcCtD
Thiabendazole—Vomiting—Etoposide—testicular cancer	0.00203	0.00203	CcSEcCtD
Thiabendazole—Rash—Etoposide—testicular cancer	0.00201	0.00201	CcSEcCtD
Thiabendazole—Dermatitis—Etoposide—testicular cancer	0.00201	0.00201	CcSEcCtD
Thiabendazole—Headache—Etoposide—testicular cancer	0.002	0.002	CcSEcCtD
Thiabendazole—Leukopenia—Epirubicin—testicular cancer	0.00196	0.00196	CcSEcCtD
Thiabendazole—Confusional state—Methotrexate—testicular cancer	0.00193	0.00193	CcSEcCtD
Thiabendazole—Anaphylactic shock—Methotrexate—testicular cancer	0.00191	0.00191	CcSEcCtD
Thiabendazole—Vision blurred—Doxorubicin—testicular cancer	0.00191	0.00191	CcSEcCtD
Thiabendazole—Convulsion—Epirubicin—testicular cancer	0.0019	0.0019	CcSEcCtD
Thiabendazole—Nausea—Etoposide—testicular cancer	0.0019	0.0019	CcSEcCtD
Thiabendazole—Anorexia—Methotrexate—testicular cancer	0.00182	0.00182	CcSEcCtD
Thiabendazole—Leukopenia—Doxorubicin—testicular cancer	0.00182	0.00182	CcSEcCtD
Thiabendazole—Confusional state—Epirubicin—testicular cancer	0.0018	0.0018	CcSEcCtD
Thiabendazole—Anaphylactic shock—Epirubicin—testicular cancer	0.00179	0.00179	CcSEcCtD
Thiabendazole—Hypotension—Methotrexate—testicular cancer	0.00179	0.00179	CcSEcCtD
Thiabendazole—Convulsion—Doxorubicin—testicular cancer	0.00176	0.00176	CcSEcCtD
Thiabendazole—Anorexia—Epirubicin—testicular cancer	0.00171	0.00171	CcSEcCtD
Thiabendazole—Somnolence—Methotrexate—testicular cancer	0.0017	0.0017	CcSEcCtD
Thiabendazole—Dyspepsia—Methotrexate—testicular cancer	0.00168	0.00168	CcSEcCtD
Thiabendazole—Hypotension—Epirubicin—testicular cancer	0.00167	0.00167	CcSEcCtD
Thiabendazole—Confusional state—Doxorubicin—testicular cancer	0.00167	0.00167	CcSEcCtD
Thiabendazole—Decreased appetite—Methotrexate—testicular cancer	0.00166	0.00166	CcSEcCtD
Thiabendazole—Anaphylactic shock—Doxorubicin—testicular cancer	0.00166	0.00166	CcSEcCtD
Thiabendazole—Fatigue—Methotrexate—testicular cancer	0.00165	0.00165	CcSEcCtD
Thiabendazole—Somnolence—Epirubicin—testicular cancer	0.00159	0.00159	CcSEcCtD
Thiabendazole—Anorexia—Doxorubicin—testicular cancer	0.00158	0.00158	CcSEcCtD
Thiabendazole—Feeling abnormal—Methotrexate—testicular cancer	0.00158	0.00158	CcSEcCtD
Thiabendazole—Dyspepsia—Epirubicin—testicular cancer	0.00158	0.00158	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Methotrexate—testicular cancer	0.00156	0.00156	CcSEcCtD
Thiabendazole—Decreased appetite—Epirubicin—testicular cancer	0.00156	0.00156	CcSEcCtD
Thiabendazole—Hypotension—Doxorubicin—testicular cancer	0.00155	0.00155	CcSEcCtD
Thiabendazole—Fatigue—Epirubicin—testicular cancer	0.00154	0.00154	CcSEcCtD
Thiabendazole—Abdominal pain—Methotrexate—testicular cancer	0.00151	0.00151	CcSEcCtD
Thiabendazole—Feeling abnormal—Epirubicin—testicular cancer	0.00147	0.00147	CcSEcCtD
Thiabendazole—Somnolence—Doxorubicin—testicular cancer	0.00147	0.00147	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Epirubicin—testicular cancer	0.00146	0.00146	CcSEcCtD
Thiabendazole—Dyspepsia—Doxorubicin—testicular cancer	0.00146	0.00146	CcSEcCtD
Thiabendazole—Decreased appetite—Doxorubicin—testicular cancer	0.00144	0.00144	CcSEcCtD
Thiabendazole—Fatigue—Doxorubicin—testicular cancer	0.00143	0.00143	CcSEcCtD
Thiabendazole—Abdominal pain—Epirubicin—testicular cancer	0.00141	0.00141	CcSEcCtD
Thiabendazole—Hypersensitivity—Methotrexate—testicular cancer	0.00141	0.00141	CcSEcCtD
Thiabendazole—Asthenia—Methotrexate—testicular cancer	0.00137	0.00137	CcSEcCtD
Thiabendazole—Feeling abnormal—Doxorubicin—testicular cancer	0.00136	0.00136	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Doxorubicin—testicular cancer	0.00135	0.00135	CcSEcCtD
Thiabendazole—Pruritus—Methotrexate—testicular cancer	0.00135	0.00135	CcSEcCtD
Thiabendazole—Hypersensitivity—Epirubicin—testicular cancer	0.00132	0.00132	CcSEcCtD
Thiabendazole—Abdominal pain—Doxorubicin—testicular cancer	0.00131	0.00131	CcSEcCtD
Thiabendazole—Diarrhoea—Methotrexate—testicular cancer	0.00131	0.00131	CcSEcCtD
Thiabendazole—Asthenia—Epirubicin—testicular cancer	0.00128	0.00128	CcSEcCtD
Thiabendazole—Pruritus—Epirubicin—testicular cancer	0.00127	0.00127	CcSEcCtD
Thiabendazole—Dizziness—Methotrexate—testicular cancer	0.00126	0.00126	CcSEcCtD
Thiabendazole—Diarrhoea—Epirubicin—testicular cancer	0.00122	0.00122	CcSEcCtD
Thiabendazole—Hypersensitivity—Doxorubicin—testicular cancer	0.00122	0.00122	CcSEcCtD
Thiabendazole—Vomiting—Methotrexate—testicular cancer	0.00122	0.00122	CcSEcCtD
Thiabendazole—Rash—Methotrexate—testicular cancer	0.00121	0.00121	CcSEcCtD
Thiabendazole—Dermatitis—Methotrexate—testicular cancer	0.0012	0.0012	CcSEcCtD
Thiabendazole—Headache—Methotrexate—testicular cancer	0.0012	0.0012	CcSEcCtD
Thiabendazole—Asthenia—Doxorubicin—testicular cancer	0.00119	0.00119	CcSEcCtD
Thiabendazole—Dizziness—Epirubicin—testicular cancer	0.00118	0.00118	CcSEcCtD
Thiabendazole—Pruritus—Doxorubicin—testicular cancer	0.00117	0.00117	CcSEcCtD
Thiabendazole—Vomiting—Epirubicin—testicular cancer	0.00114	0.00114	CcSEcCtD
Thiabendazole—Nausea—Methotrexate—testicular cancer	0.00114	0.00114	CcSEcCtD
Thiabendazole—Diarrhoea—Doxorubicin—testicular cancer	0.00113	0.00113	CcSEcCtD
Thiabendazole—Rash—Epirubicin—testicular cancer	0.00113	0.00113	CcSEcCtD
Thiabendazole—Dermatitis—Epirubicin—testicular cancer	0.00113	0.00113	CcSEcCtD
Thiabendazole—Headache—Epirubicin—testicular cancer	0.00112	0.00112	CcSEcCtD
Thiabendazole—Dizziness—Doxorubicin—testicular cancer	0.00109	0.00109	CcSEcCtD
Thiabendazole—Nausea—Epirubicin—testicular cancer	0.00106	0.00106	CcSEcCtD
Thiabendazole—Vomiting—Doxorubicin—testicular cancer	0.00105	0.00105	CcSEcCtD
Thiabendazole—Rash—Doxorubicin—testicular cancer	0.00104	0.00104	CcSEcCtD
Thiabendazole—Dermatitis—Doxorubicin—testicular cancer	0.00104	0.00104	CcSEcCtD
Thiabendazole—Headache—Doxorubicin—testicular cancer	0.00104	0.00104	CcSEcCtD
Thiabendazole—Nausea—Doxorubicin—testicular cancer	0.000983	0.000983	CcSEcCtD
